Atheneos Ventures
Atheneos Ventures is a venture capital firm based in Santa Clara, California, established in 2009. It operates as an evergreen fund focused on early-stage investments in the life sciences sector, particularly targeting companies involved in orphan drugs and rare diseases. Atheneos Ventures aims to identify and support high-quality, high-risk healthcare companies that have the potential to significantly impact patient care. The firm invests across various regions, including the United States, Canada, Australia, Singapore, and East Asia, with a particular emphasis on pharmaceuticals and biotechnology.
Armetheon, Inc. is a clinical stage biopharmaceutical company based in the San Francisco Bay area that focuses on developing novel drugs to address significant unmet medical needs. The company is working on several clinical programs, including innovative anticoagulants and antibiotics aimed at treating cardiovascular diseases. One of its key drug candidates is an anti-arrhythmic medication designed for the treatment of ventricular tachycardia in patients with implantable cardioverter defibrillators. This approach enables healthcare providers to offer treatments with improved efficacy, safety, and overall utility for patients suffering from these conditions.
Armetheon, Inc. is a clinical stage biopharmaceutical company based in the San Francisco Bay area that focuses on developing novel drugs to address significant unmet medical needs. The company is working on several clinical programs, including innovative anticoagulants and antibiotics aimed at treating cardiovascular diseases. One of its key drug candidates is an anti-arrhythmic medication designed for the treatment of ventricular tachycardia in patients with implantable cardioverter defibrillators. This approach enables healthcare providers to offer treatments with improved efficacy, safety, and overall utility for patients suffering from these conditions.
Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.